Subscription commitments
As previously announced, all members of the Board and management team, as well as most of the Company’s employees, have committed to subscribe for shares amounting to a total of approximately SEK 3.4 million. Of this amount, the Company’s CEO and Board member Ulf Bladin has committed to subscribe for shares worth SEK 1 million. In addition, ITL has committed to subscribe for shares amounting to SEK 9.9 million, with payment to be made through set-off against future costs associated with the completion of the instrument development and the production of pilot instruments to be used in the clinical performance study.

In addition to the previously communicated subscription commitments, the Company can now announce that further existing shareholders and external investors have submitted subscription commitments totaling approximately SEK 2.9 million, corresponding to approximately 2.9 percent of the Rights Issue. These existing shareholders and external investors have expressed a strong long-term interest in the Company, ahead of a period marked by significant milestones such as the whole blood study at St. Thomas’ Hospital, intensified partnership discussions, and commercialization in 2026.

In total, the Rights Issue is thus covered by subscription commitments amounting to approximately SEK 16.2 million, corresponding to approximately 16.1 percent of the Rights Issue. No compensation will be paid for the submitted subscription commitments. The commitments are not secured pledged assets, restricted funds or similar arrangements.

Lock-up agreement

In addition to the subscription commitment, ITL has undertaken to the Company not to sell or transfer shares before September 30, 2026, under a lock-up agreement. The lock-up undertaking covers all shares that ITL's subscription commitment corresponds to.

Indicative timetable

Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.